Connecticut is currently home to 1239 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
FLIGHT Study for Childhood Chronic Illness
NCT06377384
Recruiting
The FLIGHT study is an open-label, single-arm, pilot and feasibility study of a personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care for children with chronic illness. A mixed methods outcomes evaluation will be performed. The primary goal of this study is to evaluate the most feasible and promising strategies to inform a more streamlined and scalable intervention in the future. Up to 14 participa... Read More
Gender:
ALL
Ages:
Between 2 years and 15 years
Trial Updated:
04/19/2024
Locations: Epidemic Answers, Windsor, Connecticut
Conditions: Chronic Illnesses, Multiple
Register for Updates
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
NCT06028373
Recruiting
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Connecticut Eye Consultants, P.C. Danbury Eye Physicians & Surgeons, Danbury, Connecticut
Conditions: Neurotrophic Keratopathy
Register for Updates
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Ulcerative Colitis, Crohn Disease
Register for Updates
STIMIT Activator 1 IDE Pivotal Study
NCT05883163
Recruiting
The study is a prospective, multi-center, randomized, controlled study using adaptive design to assess the evidence of safety and performance of the STIMIT Activator 1 System in the treatment of patients who have been mechanically ventilated for up to 48 hours and are predicted to require additional minimum 48 hours of mechanical ventilation or longer (adding up to MV time approximately 96 hours or longer).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/11/2024
Locations: YALE New Haven Hospital, New Haven, Connecticut
Conditions: Diaphragm Issues
Register for Updates
Eversense® Non-adjunctive Use Post Approval Study
NCT04836546
Recruiting
This is a non-blinded, prospective, multi-center, single arm longitudinal cohort study (patient serving as their own control), to evaluate the effectiveness of diabetes with the Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or Type 2 diabetes. Subjects will serve as their own control, with their baseline based on using SMBG to manage their diabetes for the first 6 months followed by us... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: CMR of Greater New Haven, Hamden, Connecticut
Conditions: Diabetes
Register for Updates
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care
NCT04661072
Recruiting
The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.
Gender:
FEMALE
Ages:
13 years and above
Trial Updated:
04/09/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Congenital Uterine Anomaly
Register for Updates
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Register for Updates
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954
Recruiting
Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Malignant Neoplasm of Breast
Register for Updates
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
NCT04406831
Recruiting
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Nuvance Health, Norwalk, Connecticut
Conditions: Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
Register for Updates
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
NCT03937453
Recruiting
The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early stage pancreatic cancer or precursor lesions. Participants will be asked to donate a blood sample at specific intervals for the creation of a bio-bank necessary for the development of a blood based screening test for pan... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/29/2024
Locations: Nuvance Health, Norwalk, Connecticut
Conditions: Pancreatic Cancer, Pancreatic Neoplasms
Register for Updates